GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GlaxoSmithKline Pharmaceuticals has submitted a routine compliance certificate to the stock exchanges for the quarter ended 30th June 2025. The certificate was issued by KFin Technologies Limited, the company's Registrar and Share Transfer Agent, as required under SEBI's depositories regulations. It confirms that all share certificates received for dematerialisation during the quarter were properly processed, verified, and the depositories' names were updated in the company's register of members within 30 days. No rejected dematerialisation requests or irregularities were flagged in this filing.
This is a standard quarterly regulatory compliance filing with no material impact on the business, financials, or share price. Investors can take it as confirmation that share transfer and demat operations are running smoothly.